Date: 2015-12-02
Type of information: Collaboration agreement
Compound: hsa-miR-31-3p biomarker
Company: Integragen (France) University Hospital Grosshadern (GErmany)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration clinical research
Action mechanism: biomarker
Disease: metastatic colorectal cancer (mCRC)
Details: * On December 2, 2015, IntegraGen, a French company specializing in decoding the human genome and the development and marketing of molecular diagnostic testing in oncology and autism, announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy. The FIRE-3 study is a phase 3 clinical trial comparing outcomes of 592 KRAS Exon 2 wild-type stage IV colorectal cancer patients randomized to receive FOLFIRI therapy (5-FU, folinic acid and irinotecan) in combination with either cetuximab or bevacizumab. The present collaboration with IntegraGen will explore the expression level of hsa-miR-31-3p in primary tumors from patients enrolled in the FIRE-3 study with the goal of providing further evidence of the ability of miR-31-3p to predict clinical outcomes in patients treated with anti-EGFR therapies. “This collaboration with IntegraGen will permit us to further understand the differences in clinical outcomes we have reported for patients enrolled in the FIRE-3 study,” commented Professor Volker Heinemann, from the Department of Medical Oncology and Comprehensive Cancer Center at University Hospital Grosshadern in Munich, Germany and lead investigator for the FIRE-3 study. “Our objective with this research is to identify biomarkers which can predict outcome differences in metastatic colorectal cancer patients treated with anti-EGFR and to potentially better understand the impact of sequential treatments with these agents on patient survival.”
Financial terms:
Latest news:
